Use of a mulberry extract in the preparation of a product for treating and/or improving polycystic ovarian syndrome. It is demonstrated in the experiment that the mulberry twig alkaloids can reduce the ovarian weight of rats with polycystic ovarian syndrome and improve the ovarian pathology, regulate the estrous cycle of rats with polycystic ovarian syndrome in the intervention process, and can remarkably adjust the secretion level of sex hormones in rats with polycystic ovarian syndrome.
A61P 15/08 - Médicaments pour le traitement des troubles génitaux ou sexuelsContraceptifs pour les troubles gonadiques ou pour augmenter la fertilité, p. ex. inducteurs d'ovulation ou de spermatogénèse
2.
USE OF MULBERRY TWIG ALKALOIDS IN PREPARATION OF DRUG FOR TREATING POLYCYSTIC OVARIAN SYNDROME
Use of a mulberry extract in the preparation of a product for treating and/or improving polycystic ovarian syndrome. It is demonstrated in the experiment that the mulberry twig alkaloids can reduce the ovarian weight of rats with polycystic ovarian syndrome and improve the ovarian pathology, regulate the estrous cycle of rats with polycystic ovarian syndrome in the intervention process, and can remarkably adjust the secretion level of sex hormones in rats with polycystic ovarian syndrome.
A use of a mulberry extract in the preparation of a drug for alleviating and/or treating thyroid diseases. The use is a use of the mulberry extract in the preparation of a product for treating and/or alleviating thyroid diseases. Experiments prove that the mulberry extract can regulate the secretion levels of TSH, FT3 and FT4 of SD rats with hyperthyroidism or hypothyroidism, regulate the thyroid antibody levels of patients with Hashimoto's thyroiditis, and have a good alleviation effect on thyroid tissue lesions. As a component derived from natural plants, the mulberry extract has the advantages of small toxic and side effects, and mild and long-lasting effects.
A61P 5/16 - Médicaments pour le traitement des troubles du système endocrinien des hormones thyroïdiennes, p. ex. T3, T4 pour réduire, bloquer ou contrarier l'activité des hormones thyroïdiennes
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
4.
METHOD FOR TREATING AND PREVENTING ULCERATIVE COLITIS AND METHOD FOR DAI REDUCTION
The invention discloses a use of a mulberry (Morus alba L.) extract, including a method for treating ulcerative colitis, a method for preventing ulcerative colitis, and a method for reduction in Disease Activity Index, DAI. The use is application of a mulberry extract to the preparation of a product for treating and/or preventing ulcerative colitis. The invention experimentally demonstrated that positive drug group, SZ-A-1, SZ-A-2, SZ-A-3, SZ-A-4 and SZ-A-5 (pretreatment) could each significantly inhibit colonic atrophy in UC model mice, and the effects in SZ-A-2, SZ-A-3 and SZ-A-4 groups are comparable to that in positive drug group, with SZ-A-5 (pretreatment) achieving a superior effect to the positive drug. The mulberry extract of the invention, as a component derived from natural plants, has unique advantages of small toxic and side effects, mild and lasting actions etc.
A61P 1/04 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des ulcères, des gastrites ou des œsophagites par reflux, p. ex. antiacides, antisécrétoires, protecteurs de la muqueuse
5.
Use of Extract from Morus alba L. in the Preparation of a Medicament for Preventing and/or Treating a Hepatobiliary Disease
The present invention discloses applications of extracts from Morus alba L. Disclosed by the present invention is a use of extracts from Morus alba L. in the preparation of a product for alleviating, preventing and/or treating a hepatobiliary disease. The present invention demonstrated experimentally that extracts from Morus alba L. have effects of reducing hepatic lipid content and alleviating hepatic fibrosis in NAFLD mice gavaged with extracts from Morus alba L., thereby alleviating high-fat diet-induced fatty liver without toxic and side effects on liver and kidney. The drug of the present invention exerts multi-target pharmacological effects through multi-components, and specifically can regulate the hepatic lipid content by regulating the synthesis and oxidation of fatty acids, and can also affect hepatic fibrosis, which is more conducive to the treatment of a non-alcoholic fatty liver disease.
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
6.
USE OF MULBERRY EXTRACT IN PREPARATION OF DRUG FOR PREVENTING AND/OR TREATING HEPATOBILIARY DISEASES
A mulberry extract, which can adjust fatty acid synthesis and oxidation to adjust liver lipid content and affect the degree of liver fibrosis, and is used for preparing products for relieving, preventing and/or treating hepatobiliary diseases such as non-alcoholic fatty liver caused by high fat diet.
A61K 31/445 - Pipéridines non condensées, p. ex. pipérocaïne
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61K 127/00 - Parties de plantes contenant des feuilles ou obtenues à partir de feuilles
A61K 125/00 - Parties de plantes contenant des racines, des bulbes, des tubercules ou des rhizomes, ou obtenues à partir de ces éléments
A61K 135/00 - Parties de plantes contenant des tiges, des queues, des branches, des brindilles ou des pousses, ou obtenues à partir de ces éléments
The present disclosure relates a method for reducing animal weight, comprising administering to a patient in need thereof a therapeutically or prophylactically effective amount of a mulberry extract. The mulberry extract comprises: 3% to 99% of an alkaloid, 0.2% to 70% of a polysaccharide, 0% to 50% of an amino acid, 0% to 10% of flavone, and 0% to 25% of other components. The mulberry extract of the present disclosure can be used for controlling weight gain, and has a good therapeutic effect on type 2 diabetes with obesity.
Use of a mulberry extract in the preparation of a product for preventing and/or treating chronic kidney disease. The mulberry extract can improve renal function indexes of ZDF rats, improve serum oxidation/nitrification stress and inflammation-related indexes of the ZDF rats, reduce serum inflammatory factor levels in the ZDF rats, and improve renal pathological changes and renal fibrosis in the ZDF rats. The mulberry extract can also significantly reduce serum creatinine and urea nitrogen levels in CKD rats, and meanwhile, relieve the increase of kidney-to-body ratio.
Disclosed in the present invention is an application of a mulberry extract. The application is an application of the mulberry extract in the preparation of a product for treating and/or preventing ulcerative colitis. In the present invention, experiments prove that a positive drug group, SZ-A-1, SZ-A-2, SZ-A-3, SZ-A-4 and SZ-A-5 (pretreatment) can all significantly inhibit the atrophy of the colon of a UC model mouse. The effect of SZ-A-2, SZ-A-3 and SZ-A-4 groups is equivalent to that of the positive drug group, and the colon atrophy inhibition effect of SZ-A-5 (pretreatment) is better than that of the positive drug group. The mulberry extract provided by the invention, as a component derived from natural plants, has the unique advantages of having small toxic and side effects, and mild and lasting effects. Therefore, the mulberry extract with greatly improved medication safety has great advantages in treating ulcerative colitis.
A61P 1/04 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des ulcères, des gastrites ou des œsophagites par reflux, p. ex. antiacides, antisécrétoires, protecteurs de la muqueuse
A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
A61K 135/00 - Parties de plantes contenant des tiges, des queues, des branches, des brindilles ou des pousses, ou obtenues à partir de ces éléments
A61K 129/00 - Parties de plantes contenant de l'écorce ou obtenues à partir d'écorce
A61K 127/00 - Parties de plantes contenant des feuilles ou obtenues à partir de feuilles
10.
USE OF MULBERRY TWIG ALKALOIDS IN PREPARATION OF DRUG FOR TREATING POLYCYSTIC OVARIAN SYNDROME
Use of a mulberry extract in the preparation of a product for treating and/or improving polycystic ovarian syndrome. It is demonstrated in the experiment that the mulberry twig alkaloids can reduce the ovarian weight of rats with polycystic ovarian syndrome and improve the ovarian pathology, regulate the estrous cycle of rats with polycystic ovarian syndrome in the intervention process, and can remarkably adjust the secretion level of sex hormones in rats with polycystic ovarian syndrome.
A61P 15/08 - Médicaments pour le traitement des troubles génitaux ou sexuelsContraceptifs pour les troubles gonadiques ou pour augmenter la fertilité, p. ex. inducteurs d'ovulation ou de spermatogénèse
11.
USE OF EXTRACT OF MORI FOLIUM IN PREPARATION OF DRUG FOR TREATING PANCREATIC-RELATED DISEASES
A use of an extract of Mori folium or a main active ingredient thereof in the preparation of a product for preventing and/or treating a pancreatic-related disease. The pancreatic-related disease is selected from at least one of diabetes and pancreatitis caused by abnormal function of islet β cells. The extract of Mori folium comprises at least one of 1-deoxynojirimycin, buckwheat base, 1,4-dideoxy-1,4-imino-D-ribitol and other active ingredients.
A61P 1/18 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles pancréatiques, p. ex. enzymes pancréatiques
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
A61P 5/50 - Médicaments pour le traitement des troubles du système endocrinien des hormones pancréatiques pour augmenter ou potentialiser l'activité de l'insuline
12.
USE OF MULBERRY EXTRACT IN PREPARATION OF DRUG FOR REDUCING WEIGHT OF ANIMAL
The use of a mulberry extract in the preparation of a drug for reducing the weight of an animal. The mulberry extract contains 3%-99% of an alkaloid, 0.2%-70% of a polysaccharide, 0-50% of an amino acid, 0-10% of flavone and 0-25% of other components. The mulberry extract can be used for controlling weight gain, and has a good therapeutic effect on type 2 diabetes with obesity.
The present disclosure relates to use of a mulberry extract in preparation of a drug for reducing animal weight. The mulberry extract comprises: 3% to 99% of an alkaloid, 0.2% to 70% of a polysaccharide, 0% to 50% of an amino acid, 0% to 10% of flavone, and 0% to 25% of other components. The mulberry extract of the present disclosure can be used for controlling weight gain, and has a good therapeutic effect on type 2 diabetes with obesity.
A plant extraction method includes the following steps: 1) preparation of a crude plant extraction solution; 2) separation of the crude extraction solution through a cation resin and an optional anion resin to obtain a collection solution; 3) concentration of the collection solution obtained in step 2); 4) alcohol precipitation of the concentration solution obtained in step 3); and optionally, step 5) concentration and drying. The method can effectively reduce the content of heavy metals in an extract, and reduce the amount of ethanol used in extraction, thereby improving the product quality and lowering the production cost, and the efficiency and safety of industrial production are improved. The extract obtained by this method can be used to prepare drugs for lowering blood lipid, treating abnormal glucose tolerance, treating diseases related to abnormal blood glucose, or regulating intestinal flora, and can be processed into food products, health-care products or drinks.
Disclosed is a plant extraction method, comprising the following steps: 1) preparation of a crude plant extraction solution; 2) separation of the crude extraction solution through a cation resin and an optional anion resin to obtain a collection solution; 3) concentration of the collection solution obtained in step 2); 4) alcohol precipitation of the concentration solution obtained in step 3); and optionally, step 5) concentration and drying. The method can effectively reduce the content of heavy metals in an extract, and reduce the amount of ethanol in an extraction process, thereby improving the product quality and lowering the production cost, and industrial production efficiency and safety are improved. The extract obtained by means of the method can be used to prepare drugs for reducing fat, treating abnormal glucose tolerance, treating diseases related to abnormal blood glucose, and regulating intestinal flora, and can be processed into food products, health-care products or drinks.
Disclosed is a plant extraction method, comprising the following steps: 1) preparation of a crude plant extraction solution; 2) separation of the crude extraction solution through a cation resin and an optional anion resin to obtain a collection solution; 3) concentration of the collection solution obtained in step 2); 4) alcohol precipitation of the concentration solution obtained in step 3); and optionally, step 5) concentration and drying. The method can effectively reduce the content of heavy metals in an extract, and reduce the amount of ethanol in an extraction process, thereby improving the product quality and lowering the production cost, and industrial production efficiency and safety are improved. The extract obtained by means of the method can be used to prepare drugs for reducing fat, treating abnormal glucose tolerance, treating diseases related to abnormal blood glucose, and regulating intestinal flora, and can be processed into food products, health-care products or drinks.
brevets
